Cabiotraxetan CAS:451478-45-8 is a type of small molecule drug that is composed of several functional groups. The drug belongs to a class of compounds known as radiopharmaceuticals, which are used for imaging and therapy in nuclear medicine.
Cabiotraxetan contains a traxetan group, which is a macrocyclic chelator used to bind radioactive isotopes to the drug. The chelator acts as a cage, enclosing the isotope and preventing it from interacting with other molecules in the body. Cabiotraxetan also contains a carboxylic acid group, which is important for the chemical reactivity and solubility of the compound.
In terms of its mechanism of action, Cabiotraxetan is used as a radiopharmaceutical for imaging and therapy of certain types of cancer, particularly prostate cancer. The drug is labeled with a radioactive isotope of technetium (Tc-99m), which emits gamma rays that can be detected by a gamma camera. The gamma rays provide information about the location and size of the tumor, allowing physicians to diagnose and monitor the progression of the disease. In addition, Cabiotraxetan can also be used for targeted therapy of prostate cancer, where the radioactive isotope can selectively kill cancer cells in the prostate gland.
Cabiotraxetan represents an important advance in the development of radiopharmaceuticals for the diagnosis and treatment of cancer. By combining a traxetan chelator with a radioactive isotope, this drug provides a targeted and effective approach for imaging and therapy of certain types of cancer, particularly prostate cancer.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
